Summary
McKesson Corporation's Q2 fiscal year 2023 (ended September 29, 2022) report shows a significant increase in revenue, primarily driven by growth in its U.S. Pharmaceutical segment, which benefited from market expansion, higher drug utilization, and new product launches. Despite revenue growth, gross profit saw a slight decrease due to factors including divestitures in the International segment and foreign currency fluctuations. The company also reported a substantial increase in diluted earnings per common share from continuing operations, attributed to favorable adjustments from the remeasurement of its EU disposal group and a lower share count resulting from ongoing share repurchases. The company's strategic initiatives, including recent acquisitions like Rx Savings Solutions and the formation of an oncology research business, along with the completion of its EU divestiture, are shaping its future. McKesson continues to prioritize returning capital to shareholders through significant share repurchases and dividend payments, demonstrating a commitment to shareholder value while managing its substantial opioid-related litigation liabilities.
Financial Highlights
52 data points| Revenue | $70.16B |
| Cost of Revenue | $67.06B |
| Gross Profit | $3.10B |
| SG&A Expenses | $1.95B |
| Operating Expenses | $1.97B |
| Operating Income | $1.12B |
| Interest Expense | $55.00M |
| Net Income | $926.00M |
| EPS (Basic) | $6.47 |
| EPS (Diluted) | $6.42 |
| Shares Outstanding (Basic) | 143.10M |
| Shares Outstanding (Diluted) | 144.10M |
Key Highlights
- 1Revenue increased by 5% to $70.16 billion for the three months ended September 30, 2022, driven by growth in the U.S. Pharmaceutical segment.
- 2Diluted earnings per common share from continuing operations surged by 278% to $6.46 for the quarter, significantly boosted by favorable fair value remeasurements and reduced share count.
- 3The company completed the sale of its EU disposal group on October 31, 2022, receiving net cash proceeds of $892 million.
- 4McKesson announced the completion of two strategic acquisitions: Rx Savings Solutions, LLC, and the formation of an oncology research business with HCA Healthcare, Inc.
- 5Total operating expenses decreased by 30% for the quarter, primarily due to lower Selling, Distribution, General, and Administrative (SDG&A) expenses and favorable remeasurement of the EU disposal group.
- 6The company returned $1.6 billion to shareholders in the first half of fiscal 2023 through share repurchases and dividend payments, with an additional $4.0 billion authorized for future repurchases.
- 7The estimated accrued liability for opioid-related claims remained substantial at $7.3 billion as of September 30, 2022.